Hematology/Oncology

Top Story

Tecentriq–Avastin regimen extends PFS in PD-L1–positive advanced renal cell carcinoma

Tecentriq–Avastin regimen extends PFS in PD-L1–positive advanced renal cell carcinoma
February 20, 2017

The combination of atezolizumab and bevacizumab conferred no significant PFS benefit compared with sunitinib monotherapy among patients with locally advanced or metastatic renal cell carcinoma, according to an intention-to-treat analysis of a phase 2 study presented at Genitourinary Cancers Symposium.

However, atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech) significantly extended PFS compared with sunitinib (Sutent, Pfizer) monotherapy among patients whose disease expressed PD-L1.

In the Journals Plus

Worsening menopause-specific quality of life influences decision to end chemoprevention therapy

February 20, 2017
Negative changes in menopause-specific quality of life can influence a woman’s choice to end breast cancer chemoprevention therapy, according to study data

Olaparib extends PFS in BRCA–mutated metastatic breast cancer

February 20, 2017
A phase 3 trial designed to compare the PARP inhibitor olaparib with chemotherapy in patients with BRCA–mutated, HER-2–negative metastatic breast cancer met…
In the Journals Plus

Emotional distress may lead to unnecessary treatment for prostate cancer

February 20, 2017
Men with emotional distress after a prostate cancer diagnosis may be more likely to choose aggressive treatment, such as surgery rather than active surveillance…
In the Journals Plus

Sorafenib benefit dependent on hepatitis status in patients with HCC

February 19, 2017
Sorafenib improved OS among patients with hepatocellular carcinoma who were hepatitis C positive but hepatitis B negative, suggesting that the beneficial effects of…
More News Headlines »
CME

Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
Video
Meeting News

VIDEO: Down syndrome does not affect management of pediatric ALL

January 5, 2017
More »
Featured
CME

Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going

This activity is supported by an educational grant from Genentech.

Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement